API
< Back to situation

[REVISION HISTORY]

Indian Supreme Court litigation over medicine pricing

22 recorded revisions of this situation.

What changed

2026-11-11 14:53 UTC → 2026-11-13 11:12 UTC · added removed

Advocate Ashwini Upadhyay filed a Public Interest Litigation (PIL) in the Supreme Court of India seeking a uniform national framework to address the manufacture and sale of counterfeit and adulterated medicines. The petition, prompted by reports of a racket in Karnataka involving fake cancer drugs and critical-care injections, called for stricter penalties, including the confiscation of assets from manufacturers and financiers. Subsequently, the Supreme Court declined to adjudicate the petition, instead forwarding it to the government as a representation for consideration. The Supreme Court has since shifted focus toward pharmaceutical pricing disparities. A bench expressed severe concern over the massive gap between supply prices and maximum retail prices (MRP), describing the situation as ‘carnage’. The court highlighted instances where cancer drugs supplied to retailers for approximately Rs 2,700 carried an MRP of Rs 27,000, and flagged practices by corporate hospitals that mandate the use of in-house pharmacies. In response, the National Pharmaceutical Pricing Authority (NPPA) implemented a Trade Margin Rationalisation (TMR) measure to cap margins at 30% for 137 non-scheduled anti-cancer drugs. As of November 9, 2026, revised prices for 1,364 anti-cancer drug formulations have come into effect. Following the implementation, 85 pharmaceutical companies reported revised MRPs covering 121 drugs. Of these, 679 brands reported price reductions exceeding 50 percent, with the highest reduction reaching 96.45 percent. For instance, the breast cancer treatment capsule ‘Palpro’ reportedly dropped from Rs 40,421.33 to Rs 2,720. The Ministry of Chemicals and Fertilizers estimates these reductions will save consumers approximately Rs 3,540.38 crore annually. While doctors and patient organizations have hailed To ensure compliance, the reform, consumer advocates noted remaining gaps, pointing out that some expensive, exclusive therapies remain unaffected because NPPA has ordered strict monitoring of the caps primarily regulate middleman margins rather than direct manufacturer prices. trade margin rationalisation for these 137 drugs. Manufacturers, stockists, and medical institutions must prominently display updated price lists.

Versions

  1. 2026-11-13 11:12 UTC Indian Supreme Court litigation over medicine pricing
  2. 2026-11-11 14:53 UTC Indian Supreme Court litigation over medicine pricing
  3. 2026-11-11 02:53 UTC Indian Supreme Court litigation over medicine pricing
  4. 2026-11-09 07:49 UTC Indian Supreme Court litigation over medicine pricing
  5. 2026-11-08 05:34 UTC Indian Supreme Court litigation over medicine pricing
  6. 2026-11-07 14:59 UTC Indian Supreme Court litigation over medicine pricing
  7. 2026-11-06 16:21 UTC Indian Supreme Court litigation over medicine pricing
  8. 2026-10-31 04:36 UTC Indian Supreme Court litigation over medicine pricing
  9. 2026-10-30 03:24 UTC Indian Supreme Court litigation over medicine pricing
  10. 2026-10-29 22:51 UTC Indian Supreme Court litigation over medicine pricing
  11. 2026-10-29 03:59 UTC Indian Supreme Court litigation over medicine pricing
  12. 2026-10-28 14:42 UTC Indian Supreme Court litigation over medicine pricing
  13. 2026-10-27 13:14 UTC Indian Supreme Court litigation over medicine pricing
  14. 2026-10-23 19:04 UTC Indian Supreme Court litigation over counterfeit medicines
  15. 2026-10-23 07:17 UTC Indian Supreme Court litigation over counterfeit medicines
  16. 2026-10-20 11:35 UTC Indian Supreme Court litigation over counterfeit medicines
  17. 2026-10-19 14:13 UTC Indian Supreme Court litigation over counterfeit medicines
  18. 2026-10-18 05:11 UTC Indian Supreme Court litigation over counterfeit medicines
  19. 2026-10-17 15:02 UTC Indian Supreme Court litigation over counterfeit medicines
  20. 2026-10-12 13:12 UTC Indian Supreme Court litigation over counterfeit medicines
  21. 2026-09-30 17:08 UTC Indian Supreme Court litigation over counterfeit medicines
  22. 2026-09-29 16:12 UTC Indian Supreme Court litigation over counterfeit medicines
  23. 2026-09-28 17:53 UTC Indian Supreme Court litigation over counterfeit medicines

Select a version to see what changed compared to the one before it.